- Home
- SARO vs MRNA Comparison
SARO vs MRNA Comparison
Compare SARO & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SARO
- MRNA
- Stock Information
- Founded
- SARO 1911
- MRNA 2010
- Country
- SARO United States
- MRNA United States
- Employees
- SARO N/A
- MRNA N/A
- Industry
- SARO
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SARO
- MRNA Health Care
- Exchange
- SARO NYSE
- MRNA Nasdaq
- Market Cap
- SARO 9.3B
- MRNA 10.6B
- IPO Year
- SARO 2024
- MRNA 2018
- Fundamental
- Price
- SARO $29.31
- MRNA $26.56
- Analyst Decision
- SARO Buy
- MRNA Hold
- Analyst Count
- SARO 8
- MRNA 19
- Target Price
- SARO $34.75
- MRNA $48.13
- AVG Volume (30 Days)
- SARO 3.0M
- MRNA 14.2M
- Earning Date
- SARO 05-12-2025
- MRNA 05-01-2025
- Dividend Yield
- SARO N/A
- MRNA N/A
- EPS Growth
- SARO N/A
- MRNA N/A
- EPS
- SARO 0.23
- MRNA N/A
- Revenue
- SARO $5,437,026,000.00
- MRNA $3,177,000,000.00
- Revenue This Year
- SARO $15.54
- MRNA N/A
- Revenue Next Year
- SARO $11.37
- MRNA $8.98
- P/E Ratio
- SARO $125.12
- MRNA N/A
- Revenue Growth
- SARO 17.03
- MRNA N/A
- 52 Week Low
- SARO $21.31
- MRNA $23.15
- 52 Week High
- SARO $34.38
- MRNA $158.82
- Technical
- Relative Strength Index (RSI)
- SARO N/A
- MRNA 50.60
- Support Level
- SARO N/A
- MRNA $25.22
- Resistance Level
- SARO N/A
- MRNA $27.15
- Average True Range (ATR)
- SARO 0.00
- MRNA 1.61
- MACD
- SARO 0.00
- MRNA 0.26
- Stochastic Oscillator
- SARO 0.00
- MRNA 47.66
About SARO STANDARDAERO INC.
StandardAero Inc is a provider of aftermarket services for fixed and rotary wing aircraft gas turbine engines and auxiliary power units (APUs) to the commercial, business, and military aircraft markets. It also provides aftermarket and upgrade services for business aviation and helicopter airframes and avionics. It operates in two segments Engine Services and Component Repair Services. The group generates the majority of its revenue from the Engine Services segment which provides engine and airframe maintenance, repair, overhaul, and related services to customers in the Commercial Aerospace, Military & Helicopter, and Business Aviation end markets.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.